Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

202.91 -2.31 (-1.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout
Shares are poised to undercut their 50-day and 200-day lines, and the lower boundary of a base. 
Via Investor's Business Daily
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company... 
Via Benzinga
Core & Main Reports Downbeat Results, Joins Rev Group, PagerDuty, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes 
From Royalty Pharma plc
Via GlobeNewswire
$100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today
 
Via Benzinga
$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
 
Via Benzinga
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient... 
Via Benzinga
Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug
The company faced a number of regulatory setbacks that pushed its initial expected approval date out from April. 
Via Investor's Business Daily
Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
U.S. stock futures rise, Macy's receives higher offer, LGI Homes sells 571 homes, Telefonaktiebolaget records impairment charge, GFL declares dividend. 
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
 
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
 
Via Benzinga
(ASND) - Analyzing Ascendis Pharma's Short Interest
 
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
 
Via Benzinga
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to... 
Via Benzinga
Masters In Trading - Saturday, May 11
In this recap of the most recent trading session, I discuss earnings results and the market rally seen throughout the past week. 
Via Talk Markets
$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024
Ascendis Pharma just reported results for the first quarter of 2024. 
Via InvestorPlace
Looking Into Ascendis Pharma's Recent Short Interest
 
Via Benzinga
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
 
Via Benzinga
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
 
Via Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the... 
Via Talk Markets
These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher
Ethan Meyers, the research director at Westfield Capital Management, has a knack for identifying promising investments that have proven fruitful, especially for the Harbor Small Cap Growth Fund, where... 
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
 
Via Benzinga
How Is The Market Feeling About Ascendis Pharma?
 
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today
 
Via Benzinga
Earnings Scheduled For February 7, 2024
Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback